1 Advanced Pacemaker Operations Module 7
Mar 26, 2015
1
Advanced Pacemaker OperationsModule 7
2
Objectives
• Define: Blanking and refractory
• Complete VVI and DDD timing diagrams
– Correctly identifying PVARP, PVAB, PPAB, and TARP
– Identify events in refractory and blanking, and their effect on timing
– Correctly identify Marker Channel™ notations
• Identify upper rate behaviors
– Calculate 2:1 vs. Wenckebach rates
3
Marker Channel™
• Very useful in helping you understand how the IPG is interpreting events
• Each manufacturer has its own code
• Medtronic’s code:
– AS Atrial Sense
– AP Atrial Pace
– AR Atrial Refractory
– VS Ventricular Sense
– VP Ventricular Pace
– VR Ventricular Refractory
4
What Do You Think Would Happen Next If…
• The QRS was sensed by the atrial channel?
The next atrial pace would be inhibited because the pacemaker thinks the QRS is a P-wave.
Obviously, this is not how we want a DDD pacemaker to behave. This was a problem in early pacemakers.
Click for Answer
DDD 60
AS
AP
VP
Note: The Marker Channel tells you how the pacemaker is interpreting these events.
5
What Do You Think Would Happen Next If…
• These T-waves were sensed by the ventricular channel?
VP
VS
VP
VSClick for Answer
Programmed: VVI 60
Actual Rate: 50 bpm or 1200 ms
6
Blanking and Refractory Periods
• Blanking Period
– A period of time during which the sense amplifiers are off, and the pacemaker is “blind”
– Some blanking periods are programmable, some are non-programmable
• Refractory Period
– A period of time during which sensed events are ignored for timing purposes, but included in diagnostic counters
– Some refractory periods are programmable, some non-programmable
7
Why Do We Use Refractory and Blanking Periods?
• Pacemaker sensing occurs when a signal is large enough to cross the sensing threshold
1.25 mV Sensitivity
Time
5.0 mV
2.5 mV
1.25 mV
Sensing does not tells us anything about the origin or morphology of the sensed event, only its “size.”
8
SENSE!
Why Do We Use Refractory and Blanking Periods?
• By manipulating the sense amplifiers, we filter signals based on their relationship
The potential for digitizing these signals may someday allow pacemakers to discriminate signals based on morphology rather than just on their relationship.
Blanking Refractory
Time
5.0 mV
2.5 mV
1.25 mV
Sensing
9
Let’s Look at the VVI Example Again…
• Now, is the T-wave sensed by the ventricular channel?
VP
VR
VP
VR
The T-wave falls in the ventricular refractory period (VR), and it is ignored for timing purposes.
Click for Answer
The VVI pacemaker is operating normally.
VVI 60
10
• Note the addition of the Blanking and Refractory periods
VVI Timing
The pacemaker applies these periods to every timing cycle.
VP
VR
VP
VR
1000 ms 1000 ms
Blanking
Refractory
VRP 320 ms VRP 320 ms
11
T-wave Sensing
• Is there another way to program the pacemaker to ignore the T-waves?
VP
VR
VP
VR
1000 ms 1000 ms
VRP 320 ms
BlankingRefractory
VRP 320 ms
We could program the pacemaker to be less sensitive (e.g., from 2.5mV to 5.0 mV). But then it might not sense every R-wave.
Click for Answer
12
Dual Chamber Timing
Refractory and Blanking Periods
ARP PVARP
VRP
PVAB
Those affecting the atrial channel are indicated above the ECG baseline.
Those affecting the ventricular channel are indicated below the ECG baseline.
Red: Blanking
Orange: Refractory period
13
ARP
Dual Chamber Timing
• Atrial Refractory and Blanking Periods
Atrial Blanking
Atrial Refractory
Period
Post Ventricular Atrial Blanking
Post Ventricular Atrial Refractory Period
PVARP
VRP
PVAB
14
Dual Chamber Timing
• Ventricular Refractory and Blanking Periods
Post Atrial Ventricular Blanking Ventricular Refractory
Period
Ventricular Blanking
VRP
ARP PVARP
PVAB
15
Dual Chamber Timing
• Atrial Pace (AP) - Ventricular Pace (VP) example
DDD 60
The pacemaker applies these periods every timing cycle.
A-A interval A-A interval
VRP
ARP PVARP
PVAB
VRP
ARP PVARP
PVAB
PAVV-A interval V-A interval
PAV
16
Dual Chamber Timing
• Lower Rate (A-A) Interval
– A-A interval indicates the minimum rate the device will pace under normal circumstances (“escape interval,” “lower rate interval”)
– In dual chamber pacemakers we subdivide this into the A-V interval (PAV or SAV) and the V-A interval
• Normally, the device is designed to always use A-A timing – to maintain a steady atrial rate
VRP
ARP PVARP
PVAB
VRP
ARP PVARP
PVAB
A-A interval A-A interval
PAV PAV
V-A interval V-A interval
17
Dual Chamber Timing
• Upper Tracking Rate (UTR)
– The maximum rate the ventricles will be paced 1:1 in response to atrial sensed events
UTR UTR
VRP
ARP PVARP
PVAB
VRP
ARP PVARP
PVAB
A-A interval A-A interval
SAV SAV
V-A interval V-A interval
18
Dual Chamber Timing
• Tracking
– 1:1 tracking (atrial sense – ventricular pace) occurs at rates above the Lower Rate, but below the Upper Tracking Rate
1:1 tracking of any atrial sense
UTR
VRP
ARP PVARP
PVAB
A-A interval A-A interval
19
In other words, the next atrial sense is getting closer to the previous ventricular event.
UTR
VRP
ARP PVARP
PVAB
SAV
A-A interval
V-A interval
VRP
ARP PVARP
PVAB
UTR
A-A interval
V-A intervalSAV
Dual Chamber Timing
• The pacemaker’s response to high atrial rates
– To a pacemaker, an increase in atrial rate means that V-A intervals are getting shorter
20
Dual Chamber TimingUpper Rate Behavior
21
Upper Rate Behavior
• Pacemaker Wenckebach
– Caused by the atrial rate exceeding the Upper Tracking Rate
22
PVARP
A-A interval
Upper Rate Behavior
• Pacemaker Wenckebach– Prolongs the SAV until upper rate limit expires
– Produces gradual change in tracking rate ratio
UTR
ARP ARP PVARP
A-A interval
SAV SAV
UTR
ARP
PAV
PVARP
UTR
A-A interval
VP
VP
VP
AS
AP
AS
AR
23
Wenckebach Example
• Pacemaker patient on an exercise test
– 4:3 Wenckebach operation
• Each AS (P-wave) is followed by an increasing SAV, and then the VP
• Eventually an atrial beat is not tracked, and a ventricular beat is dropped
24
Wenckebach Example
This P-wave fell in the PVARP of the previous cycle.
It is refractory (AR), so it is ignored for timing.
It cannot start an SAV, so it is not followed by a ventricular pace.
This is normal upper rate pacemaker behavior.
25
Upper Rate Behavior
• 2:1 Block
– Occurs when P-waves are faster than TARP
– TARP = SAV + PVARP
PVARPARP
SAVVP
AS
AR
PVARPARP
SAVVP
AS
AR
ARP
SAVVP
AS
TARP TARP TARP
26
Upper Rate Behavior
• 2:1 Block
– Caused by the atrial rate exceeding the Total Atrial Refractory Period (TARP)
27
Knowledge Check
• Given the following pacemaker parameters, what rhythm will result from an atrial rate of 130 bpm?
– UTR = 120 bpm
– SAV = 150 ms
– PVARP = 250 ms
– Pacemaker Wenckebach
• Given the same pacemaker parameters, what atrial rate would result in 2:1 block?
– An atrial rate above 150 bpm
Click for Answer
Click for Answer
28
WenckebachNo
VentricularPacing
Upper Rate Behavior
UTR
Atrial Rate
Ven
tric
ular
Rat
e
LR1:1 AtrialTracking
2:1 Block
UTRLR TARP
= Ventricular Pacing
29
WenckebachNo
VentricularPacing
Upper Rate Behavior
UTR
Atrial Rate
Ven
tric
ular
Rat
e
LR1:1 AtrialTracking
2:1 Block
UTRLR TARP
= Ventricular Pacing
30
Increased Tracking
Increased Tracking
Achieving a Higher UTR without Block
• Decrease SAV • Decrease PVARP
PVARPARP
SAV
AS
AR
TARP
SAV
AS
SAV
AS
PVARPARP
TARP
PVARPARP
SAV
AS
AR
TARP
PVARPARP
SAV
AS
TARP
SAV
AS
31
Achieving a Higher UTR without Block
• SAV and PVARP managed automatically
– Programming Rate-Adaptive AV to “On”
• This will automatically decrease the SAV/PAV as the atrial rate increases
– Programming PVARP to “Auto”
• This will automatically decrease the PVARP as the atrial rate increases
32
If Long TARP is the Problem…
• Why not just program short AV Intervals or short PVARP?
– Short AV intervals may force ventricular pacing
– Short PVARP may allow retrograde conduction to be sensed
• Consider this ECG:
• The retrograde P-waves occur outside of PVARP.
• The pacemaker tracks the retrograde P-waves.
• This is called a Pacemaker Mediated Tachycardia (PMT).
33
Status Check
AS
VR
AR
AP
VP
VS
An Atrial Sense (P-wave)
Ventricular Refractory
Atrial Refractory
Atrial Pace
Ventricular Pace
A Ventricular Sense (QRS or R-wave)
Click for Answer
Can you identify the following Marker Channel notations?
34
Status Check
VRP VRP
VP
VP
V. Blanking V. Blanking
Lower Rate Interval Lower Rate Interval
Click for Answer
Can you complete this timing diagram?
35
Status Check
• Show:
- Atrial Refractory during the AV Interval
- PVARP with PVAB
- VRP
Click for Answer
Atrial Refractory during the AV Interval
PVARP with PVAB
VRP
Complete this timing diagram
36
Status Check
• You are called to evaluate this rhythm strip
– Obtained while the patient is having an exercise test
– Clinician thinks it is loss of capture
– Patient’s underlying rhythm is CHB
• What is going on?
Click for Answer2:1 block. P-waves
37
Status Check
• What mode do you think this is?
• Calculate the Atrial and Ventricular rates
• Propose a programming solution to resolve this
Click for Answer DDD Mode. Atrial rate: 430 ms or 140 bpm, Ventricular rate: 860 ms or 70 bpm.
Increase the UTR and program RA-AV on, or Increase UTR and decrease PVARP.
430 ms 860 ms
38
Status Check
• Given the following parameters, what will occur first as the patient’s atrial rate increases? Wenckebach or 2:1 block?
– Upper Tracking Rate: 120 bpm
– SAV = 200 ms
– PVARP = 350 ms
• 2:1 block will occur first
Click for Answer
39
Brief Statements
Indications
• Implantable Pulse Generators (IPGs) are indicated for rate adaptive pacing in patients who ay benefit from increased pacing rates concurrent with increases in activity and increases in activity and/or minute ventilation. Pacemakers are also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and AV synchrony, which include various degrees of AV block to maintain the atrial contribution to cardiac output and VVI intolerance (e.g. pacemaker syndrome) in the presence of persistent sinus rhythm.
• Implantable cardioverter defibrillators (ICDs) are indicated for ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias.
• Cardiac Resynchronization Therapy (CRT) ICDs are indicated for ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias and for the reduction of the symptoms of moderate to severe heart failure (NYHA Functional Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy and have a left ventricular ejection fraction less than or equal to 35% and a QRS duration of ≥130 ms.
• CRT IPGs are indicated for the reduction of the symptoms of moderate to severe heart failure (NYHA Functional Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction less than or equal to 35% and a QRS duration of ≥130 ms.
Contraindications
• IPGs and CRT IPGs are contraindicated for dual chamber atrial pacing in patients with chronic refractory atrial tachyarrhythmias; asynchronous pacing in the presence (or likelihood) of competitive paced and intrinsic rhythms; unipolar pacing for patients with an implanted cardioverter defibrillator because it may cause unwanted delivery or inhibition of ICD therapy; and certain IPGs are contraindicated for use with epicardial leads and with abdominal implantation.
• ICDs and CRT ICDs are contraindicated in patients whose ventricular tachyarrhythmias may have transient or reversible causes, patients with incessant VT or VF, and for patients who have a unipolar pacemaker. ICDs are also contraindicated for patients whose primary disorder is bradyarrhythmia.
40
Brief Statements (continued)
Warnings/Precautions
• Changes in a patient’s disease and/or medications may alter the efficacy of the device’s programmed parameters. Patients should avoid sources of magnetic and electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device electrical reset or device damage. Do not place transthoracic defibrillation paddles directly over the device. Additionally, for CRT ICDs and CRT IPGs, certain programming and device operations may not provide cardiac resynchronization. Also for CRT IPGs, Elective Replacement Indicator (ERI) results in the device switching to VVI pacing at 65 ppm. In this mode, patients may experience loss of cardiac resynchronization therapy and / or loss of AV synchrony. For this reason, the device should be replaced prior to ERI being set.
Potential complications
• Potential complications include, but are not limited to, rejection phenomena, erosion through the skin, muscle or nerve stimulation, oversensing, failure to detect and/or terminate arrhythmia episodes, and surgical complications such as hematoma, infection, inflammation, and thrombosis. An additional complication for ICDs and CRT ICDs is the acceleration of ventricular tachycardia.
• See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website at www.medtronic.com.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
41
Brief Statement: Medtronic Leads
Indications
• Medtronic leads are used as part of a cardiac rhythm disease management system. Leads are intended for pacing and sensing and/or defibrillation. Defibrillation leads have application for patients for whom implantable cardioverter defibrillation is indicated
Contraindications
• Medtronic leads are contraindicated for the following:
• ventricular use in patients with tricuspid valvular disease or a tricuspid mechanical heart valve.
• patients for whom a single dose of 1.0 mg of dexamethasone sodium phosphate or dexamethasone acetate may be contraindicated. (includes all leads which contain these steroids)
• Epicardial leads should not be used on patients with a heavily infracted or fibrotic myocardium.
• The SelectSecure Model 3830 Lead is also contraindicated for the following:
• patients for whom a single dose of 40.µg of beclomethasone dipropionate may be contraindicated.
• patients with obstructed or inadequate vasculature for intravenous catheterization.
42
Brief Statement: Medtronic Leads (continued)
Warnings/Precautions
• People with metal implants such as pacemakers, implantable cardioverter defibrillators (ICDs), and accompanying leads should not receive diathermy treatment. The interaction between the implant and diathermy can cause tissue damage, fibrillation, or damage to the device components, which could result in serious injury, loss of therapy, or the need to reprogram or replace the device.
• For the SelectSecure Model 3830 lead, total patient exposure to beclomethasone 17,21-dipropionate should be considered when implanting multiple leads. No drug interactions with inhaled beclomethasone 17,21-dipropionate have been described. Drug interactions of beclomethasone 17,21-dipropionate with the Model 3830 lead have not been studied.
Potential Complications
• Potential complications include, but are not limited to, valve damage, fibrillation and other arrhythmias, thrombosis, thrombotic and air embolism, cardiac perforation, heart wall rupture, cardiac tamponade, muscle or nerve stimulation, pericardial rub, infection, myocardial irritability, and pneumothorax. Other potential complications related to the lead may include lead dislodgement, lead conductor fracture, insulation failure, threshold elevation or exit block.
• See specific device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website at www.medtronic.com.
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
43
Disclosure
NOTE:
This presentation is provided for general educational purposes only and should not be considered the exclusive source for this
type of information. At all times, it is the professional responsibility of the practitioner to exercise independent
clinical judgment in a particular situation.
NOTE:
This presentation is provided for general educational purposes only and should not be considered the exclusive source for this
type of information. At all times, it is the professional responsibility of the practitioner to exercise independent
clinical judgment in a particular situation.